Zyrtec-D Switch Approved – J&J Will Launch Behind The Counter This Year
This article was originally published in The Tan Sheet
Executive Summary
FDA approved Johnson & Johnson's bid to switch prescription antihistamine/nasal decongestant Zyrtec-D to nonprescription status, but the firm is still awaiting a reply on single-ingredient Zyrtec